Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Robert Wessels, M.D.

Co-Author

This page shows the publications co-authored by Michael Wessels and Dennis Kasper.
Connection Strength

2.076
  1. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun. 1998 May; 66(5):2186-92.
    View in: PubMed
    Score: 0.200
  2. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis. 1995 Apr; 171(4):879-84.
    View in: PubMed
    Score: 0.161
  3. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1993 Nov; 61(11):4760-6.
    View in: PubMed
    Score: 0.146
  4. The changing spectrum of group B streptococcal disease. N Engl J Med. 1993 Jun 24; 328(25):1843-4.
    View in: PubMed
    Score: 0.143
  5. Correct structure of repeating unit of group B Streptococcus type III capsular polysaccharide. J Infect Dis. 1990 Dec; 162(6):1412.
    View in: PubMed
    Score: 0.119
  6. Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A. 1989 Nov; 86(22):8983-7.
    View in: PubMed
    Score: 0.111
  7. Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J Exp Med. 1989 Jun 01; 169(6):2121-31.
    View in: PubMed
    Score: 0.108
  8. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun. 1989 Apr; 57(4):1089-94.
    View in: PubMed
    Score: 0.106
  9. A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc Natl Acad Sci U S A. 1987 Dec; 84(24):9170-4.
    View in: PubMed
    Score: 0.097
  10. Regulation of virulence by a two-component system in group B streptococcus. J Bacteriol. 2005 Feb; 187(3):1105-13.
    View in: PubMed
    Score: 0.080
  11. Molecular size affects antigenicity of type III, group B Streptococcus capsular polysaccharide. Trans Assoc Am Physicians. 1985; 98:384-91.
    View in: PubMed
    Score: 0.079
  12. Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem. 2001 Jan 05; 276(1):139-46.
    View in: PubMed
    Score: 0.060
  13. Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus. J Biol Chem. 2000 Mar 17; 275(11):7497-504.
    View in: PubMed
    Score: 0.057
  14. Measurement of human antibodies to type III group B Streptococcus. Infect Immun. 1999 Aug; 67(8):4303-5.
    View in: PubMed
    Score: 0.054
  15. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1999 Jan; 179(1):142-50.
    View in: PubMed
    Score: 0.052
  16. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis. 1998 Aug; 178(2):569-72.
    View in: PubMed
    Score: 0.051
  17. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996 Nov 15; 98(10):2308-14.
    View in: PubMed
    Score: 0.045
  18. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1994 Aug; 62(8):3236-43.
    View in: PubMed
    Score: 0.038
  19. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun. 1994 May; 62(5):1593-9.
    View in: PubMed
    Score: 0.038
  20. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun. 1992 Oct; 60(10):3986-93.
    View in: PubMed
    Score: 0.034
  21. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1992 Oct; 60(10):4009-14.
    View in: PubMed
    Score: 0.034
  22. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992 Jan; 89(1):203-9.
    View in: PubMed
    Score: 0.032
  23. Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide. J Biol Chem. 1991 Apr 15; 266(11):6714-9.
    View in: PubMed
    Score: 0.031
  24. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990 Nov; 86(5):1428-33.
    View in: PubMed
    Score: 0.030
  25. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem. 1990 Oct 25; 265(30):18278-83.
    View in: PubMed
    Score: 0.030
  26. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A. 1987 Oct; 84(20):7208-12.
    View in: PubMed
    Score: 0.024
  27. Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem. 1987 Jun 15; 262(17):8262-7.
    View in: PubMed
    Score: 0.023
  28. Immunochemical analysis of the types Ia and Ib group B streptococcal polysaccharides. J Immunol. 1985 Dec; 135(6):4164-70.
    View in: PubMed
    Score: 0.021
  29. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39):13950-5.
    View in: PubMed
    Score: 0.021
  30. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect Immun. 2005 May; 73(5):3096-103.
    View in: PubMed
    Score: 0.020
  31. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A. 2002 Sep 17; 99(19):12391-6.
    View in: PubMed
    Score: 0.017
  32. The alpha-L-(1----2)-trirhamnopyranoside epitope on the group-specific polysaccharide of group B streptococci. Infect Immun. 1991 May; 59(5):1690-6.
    View in: PubMed
    Score: 0.008
  33. Molecular analysis of two group B streptococcal virulence factors. Semin Perinatol. 1990 Aug; 14(4 Suppl 1):22-9.
    View in: PubMed
    Score: 0.007
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.